Open AccessA ‘real‐world’ retrospective multi‐centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis
Author(s) -
Kronsten Victoria Tatiana,
Colwill Michael J.,
Nayeemuddin Shadab,
Limdi Jimmy K.,
Selinger Christian,
Scott Glyn,
AlHillawi Lulia,
Salehi Shayon,
Blaker Paul,
ChungFaye Guy,
Kent Alexandra J.,
Dubois Patrick,
Hayee Bu
Publication year - 2021
Publication title -
gastrohep
Language(s) - English
Resource type - Journals
ISSN - 1478-1239
DOI - 10.1002/ygh2.467
Subject(s) - infliximab , adalimumab , medicine , ulcerative colitis , retrospective cohort study , maintenance therapy , surgery , rescue therapy , tumor necrosis factor alpha , chemotherapy , disease
Abstract Background Anti‐tumour necrosis factor therapy is an established treatment for moderate‐to‐severely active ulcerative colitis (UC). Recent network meta‐analyses of controlled trial data have indicated a superiority of intravenous drugs (infliximab) over subcutaneous (adalimumab). We conducted a retrospective multi‐centre cohort study to determine the comparative effectiveness of these two drugs. Methods Patients with UC administered infliximab or adalimumab as their first biologic, identified from the therapy databases of five UK hospitals, were included, if they had completed induction and were on maintenance treatment. Patients receiving infliximab as ‘rescue’ therapy for acute severe UC were excluded. The primary end‐points for comparison were the number of patients remaining on initial therapy (infliximab or adalimumab) at 52 weeks and the number of patients in clinical remission at 52 weeks (Simple Clinical Colitis Activity [SCCAI] score ≤ 3). Results Seventy‐eight infliximab and 63 adalimumab patients were analysed. At 52 weeks, 83% of infliximab patients and 59% of adalimumab patients remained on therapy ( P = 0.001). At 52 weeks, 62% of the infliximab group were in clinical remission compared to 32% of the adalimumab group ( P = 0.0004). Primary non‐response was reported in 24% of adalimumab patients and 5% of infliximab patients ( P = 0.001). There were no significant differences in colectomy rates or hospital admission for acute flares at 52 weeks. Conclusions Our real‐world results affirm the findings of network meta‐analyses of clinical trials, suggesting that infliximab is superior to adalimumab in the maintenance of remission in UC up to 52 weeks.